Skip to content
HowShorted

INTERCEPT PHARMACEUTICALS, INC. short interest in 2019

In 2019, INTERCEPT PHARMACEUTICALS, INC.'s disclosed short interest ran from 10.29% of shares outstanding on 15 Jan 2019 to 13.82% on 31 Dec 2019, a change of +3.53 percentage points. The year's high was 19.16% on 28 Jun 2019 and its low 9.61% on 31 Jan 2019, averaging 15.97% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.44 days on 31 Oct 2019. Full history: INTERCEPT PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for INTERCEPT PHARMACEUTICALS, INC. in 2019

2019 in figures

Start of year
10.29% (15 Jan 2019)
End of year
13.82% (31 Dec 2019)
Change
+3.53 pp
High
19.16% (28 Jun 2019)
Low
9.61% (31 Jan 2019)
Average
15.97%
Highest days to cover
13.44 (31 Oct 2019)
SEC filings marked
8

Every report in 2019

INTERCEPT PHARMACEUTICALS, INC. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201910.29%6.01
31 Jan 20199.61%5.10
15 Feb 201910.89%4.67
28 Feb 201916.51%1.54results (8-K)
15 Mar 201915.53%5.1810-K filed
29 Mar 201914.83%8.32
15 Apr 201915.98%3.77
30 Apr 201917.65%5.80
15 May 201918.38%5.6310-Q filed, results (8-K)
31 May 201917.99%11.08
14 Jun 201918.25%7.45
28 Jun 201919.16%11.19
15 Jul 201917.79%8.64
31 Jul 201915.61%7.80
15 Aug 201915.79%8.53results (8-K), 10-Q filed
30 Aug 201916.18%11.92
13 Sep 201916.59%10.92
30 Sep 201917.49%11.72
15 Oct 201917.41%10.63
31 Oct 201917.24%13.44
15 Nov 201917.47%10.8710-Q filed, results (8-K)
29 Nov 201916.66%7.08
13 Dec 201916.05%5.66
31 Dec 201913.82%8.16

See also: INTERCEPT PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.